Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib versus imatinib in newly diagnosed chronic-phase CML
NL-OMON40089Phase 3Active, not recruiting
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Ponatinib with Imatinib (2 arms). Primary endpoint: Major molecular response rate at 12 months. Started Jul 2013; status: active, not recruiting.
02
Drugs
ponatinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON40089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40089.